Synthetic lethality from the combination of a histone methyltransferase SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma.

Saved in:
Bibliographic Details
Title: Synthetic lethality from the combination of a histone methyltransferase SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma.
Authors: Toyohara Y; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; Division of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan., Sone K; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. ksone5274@gmail.com., Kumegawa K; Cancer Cell Diversity Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan., Yamamoto Y; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Hachijo R; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; Division of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan., Kukita A; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Taguchi A; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Ikemura M; Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Miyamoto Y; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Tanikawa M; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Iriyama T; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Mori M; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Hamamoto R; Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan.; Cancer Translational Research Team, RIKEN Center for Advanced Intelligence Project, Tokyo, Japan., Ushiku T; Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Oda K; Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Hirota Y; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Maruyama R; Division of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.; Cancer Cell Diversity Project, NEXT-Ganken Program, Japanese Foundation for Cancer Research, Tokyo, Japan., Osuga Y; Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Source: BMC cancer [BMC Cancer] 2025 Dec 16; Vol. 25 (1), pp. 1873. Date of Electronic Publication: 2025 Dec 16.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1471-2407
DOI:10.1186/s12885-025-15267-6